Adlai Nortye Ltd.

ANL

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
ANL
CIK0001944552
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address685 U.S. HIGHWAY ONE, 2ND FLOOR, NORTH BRUNSWICK, NJ, 08902
Website www.adlainortye.com
Phone848-230-7430
CEOYang Lu
EmployeesN/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$5.23 million
Pre-Tax Income$-35.53 million
Net Income$-35.53 million
Net Income to Common$-35.53 million
EPSN/A
View All
Balance Sheet
Cash$8.06 million
Assets$34.43 million
Liabilities$42.76 million
Common Equity$-8.32 million
Liabilities & Equity$34.43 million
View All
Cash Flow Statement
Calculations
NOPAT$-24.83 million
EBITDA$-34.11 million
Price to EarningsN/A
Price to BookN/A
ROE-414.01%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

H.C. Wainwright Sees “Potential Best-in-Class Potency” for Adlai Nortye’s (ANL) Lead Asset, Lifts PT

Adlai Nortye Ltd. (NASDAQ:ANL) is one of the best performing small cap stocks so far in 2026. On April 20, H.C. Wainwright lifted the price target on Adlai Nortye Ltd. (NASDAQ:ANL) to $20 from $16 while maintaining a Buy rating on the shares. The firm told investors in a research note that the company’s lead […]

Article Link

Adlai Nortye (ANL): 10 Tiny Stocks That Are On Fire Right Now

Adlai Nortye (NASDAQ:ANL) is one of the tiny stocks that are on fire right now. On April 16, Adlai Nortye entered into a securities purchase agreement for a private placement equity financing/PIPE expected to yield gross proceeds of ~$150 million. The oversubscribed transaction saw significant participation from a broad group of new and existing institutional […]

Article Link

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.

Article Link

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private plac

Article Link

Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?

Here is how Astellas Pharma Inc. (ALPMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.

Article Link